Vicore Pharma Holding AB (VICO-SE): Acquisition of INIM brings HealthCap on board

Free to access research and investor meetings in a post-MiFID2 world.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

Vicore Pharma Holding AB (VICO-SE): Acquisition of INIM brings HealthCap on board
Recommendation: OUTPERFORM
Target Price: SEK43.00
Current Price: SEK11.50 (COB on 2^nd July 2018)

KEY TAKEAWAY

Vicore has announced its intention to acquire INIM Pharma AB, a private Swedish biotech company focused on severe rare lung diseases, through a share issue that will lead to INIM's majority shareholder and leading VC firm HealthCap becoming Vicore's largest shareholder. In connection with the acquisition, Vicore's Board of Directors proposes a SEK80m rights issue and the distribution of the majority of Vicore's shareholding in recently listed I-Tech to current shareholders ahead of the acquisition and rights issue. Both transactions require approval of an EGM to be held on 13 August 2018. The acquisition of INIM complements Vicore's lead asset C21 in Phase IIa for idiopathic fibrosis ("IPF") and brings on board a successful, well-known life science investor. We expect the SEK80m rights issue plus SEK20m net cash from INIM to extend Vicore's cash runway until at least H2/2019E. We maintain our OUTPERFORM recommendation and SEK43 target price.

Acquisition of INIM Pharma AB brings in complementary asset for lung disease

INIM Pharma focuses on inhaled immunomodulatory drugs. Its lead asset, due to enter Phase I in 2019, is a local treatment for severe lung diseases such as IPF which is being developed with Nanologica using their drug delivery technology. Vicore will pay for the acquisition through the issue of 8.851m shares, diluting current shareholders by 35.8%.

Leading European VC firm HealthCap becomes Vicore's largest shareholder

Following the transaction, HealthCap, INIM's majority shareholder with an 85% share, will hold 30.4% of Vicore shares. HealthCap is a leading European venture capital firm focused on life sciences that was an early investor in multiple European biotech success stories including Algeta and Wilson, sold to Bayer and Alexion for $2.9bn and $855m, respectively. Thus, we expect Vicore to benefit from the extensive scientific, medical, operational, and financing knowledge and expertise of the seasoned HealthCap team.

SEK80m rights issue plus net cash from INIM extends cash runway to H2/2019E

The proposed rights issue of SEK80m is already covered by 56.5%, with HealthCap subscribing to its pro rata share. The resulting cash inflow, together with the SEK20m net cash on INIM's balance sheet, should extend Vicore's cash runway to at least H2/2019E on our current estimates.

Majority of I-Tech shares to be distributed to current Vicore shareholders

As part of the deal, Vicore's Board proposes to distribute the majority of the shareholding in I-Tech (listed on Nasdaq First North in May) equating to 2.075m shares to Vicore shareholders ahead of the acquisition and rights issue.

Kind regards,

Brigitte de Lima, PhD, CFA | Analyst

goetzpartners Healthcare Research Team | Research Team

goetzpartners securities Limited

The Stanley Building, 7 Pancras Square, London, N1C 4AG, England, UK.

T +44 (0) 203 859 7725 | healthcareresearch@goetzpartners.com / brigitte.delima@goetzpartners.com

www.goetzpartnerssecurities.com

Registered in England No. 04684144.

Managing Directors: Dr Stephan Goetz, Martin Brunninger and Ulrich Kinzel.

GPSL has a formal client relationship with Vicore Pharma Holding AB.

GPSL publishes and distributes "Investment" Research and "Corporate Sponsored" Research. Our Corporate Sponsored Research and investor meetings (e.g. NDRs, 1 to 1 meetings) are free to access and attend and is not classified as an inducement in a post-MiFID2 world, this is because the issuer is paying GPSL. GPSL does not offer any execution or market making services. This is a marketing communication as defined by the Financial Conduct Authority ("FCA"). The information herein is considered to be an acceptable minor non-monetary benefit as defined under FCA COBS 2.3A19(5).

In accordance with the General Data Protection Regulation ("GDPR") - if you would like to be removed / unsubscribed from our CRM (also please note that you are free to contact GPSL at any time in the future to have your e-mail subscription amended), please e-mail:
researchproduction@goetzpartners.com

About GPSL: goetzpartners securities Limited is a member of the goetzpartners group, and a leading pan European investment bank and research company. We bring together a wide range of expertise, insights and innovations to advance the interests of our clients around the world. The fast-changing environment brings challenges for businesses and investors. Research innovation, digital transformation and disruptive business ideas reshuffle the corporate world at a relentless pace. Our sector knowledge and our global footprint bring together corporate intelligence and a deep understanding of the industry with a wide network of top decision makers. These collective insights help our clients to stay at the leading edge of change.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

This e-mail (including any attachments) from goetzpartners securities Limited ("GPSL") is confidential and may contain information which is proprietary, privileged or otherwise legally protected against unauthorised use or disclosure. If you receive this e-mail in error or are not the intended recipient of this e-mail, please delete and destroy all copies in your possession, notify the sender that you have received this e-mail, and note that any review or dissemination of, or the taking of any action in reliance on this e-mail is expressly prohibited. GPSL shall not be liable for the improper or incomplete transmission of the information contained in this e-mail nor for any delay in its receipt or damage to your system. GPSL does not guarantee that the integrity of this e-mail has been maintained nor that this e-mail is free of viruses, interceptions or interference and makes no warranties in relation to these matters. This is not an offer or a solicitation to buy or sell securities or investment products, or an official confirmation. GPSL record electronic and phone communications in accordance with FCA and MiFID2 regulations, they will be monitored for regulatory and training purposes. GPSL is authorised and regulated by the Financial Conduct Authority of the United Kingdom (Firm Reference Number: 225563).

Click on the following link for the GPSL MiFID2 Investor Guidance Notice

GPSL Equity Research publications are available on the following aggregators and via news distribution circuits (For Institutional Use Only): AlphaSense, Bloomberg (GOET), Capital IQ, EQS, FACTSET, Research Tree, RNS Reach and Thomson Reuters.

If you cannot click on the above hyperlink please copy the below link and paste it into your browser for the full pdf version of the equity research report:

https://gp.bluematrix.com/sellside/EmailDocViewer?encrypt=69de5145-df11-44cf-8dc5-87ea6c7c46ad&mime=pdf&co=gp&id=paul.dunne@goetzpartners.com&source=libraryView

Free to access research and investor meetings in a post-MiFID2 world.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.